<DOC>
	<DOC>NCT00790998</DOC>
	<brief_summary>This is a Phase 3 study comparing the efficacy, safety and tolerability of moxidectin and ivermectin in subjects infected with Onchocerca volvulus, which is the parasite that causes river blindness. Subjects participating in the study will be randomly assigned (by a 2 to1 ratio) to receive one orally-administered dose of either moxidectin or ivermectin.</brief_summary>
	<brief_title>Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus Infection</brief_title>
	<detailed_description />
	<mesh_term>Onchocerciasis</mesh_term>
	<mesh_term>Intestinal Volvulus</mesh_term>
	<mesh_term>Milbemycin</mesh_term>
	<mesh_term>Ivermectin</mesh_term>
	<criteria>Male and female subjects with Onchocerca volvulus infection Pregnant or breast feeding women; coincidental loiasis</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>onchocerciasis</keyword>
	<keyword>river blindness</keyword>
	<keyword>onchocerca volvulus</keyword>
	<keyword>moxidectin</keyword>
	<keyword>ivermectin</keyword>
</DOC>